Regulatory press release28.08.2023 klo 13.01ISR's, SARS-CoV-2 dry powder nasal - vaccine booster candidate, ISR52, demonstrates superior immune response, in mouse model challenge studies compared to subcutaneous injection of this vaccine.
Regulatory press release01.07.2022 klo 11.20ISR: SARS-CoV-2 vaccine study approved by Bangladesh BMRC
Regulatory press release28.06.2022 klo 16.00ISR signs development agreements with Catalent to scale-up its spray-dried nasal vaccine, powder formulation for Phase III.
Regulatory press release28.06.2022 klo 16.00ISR signs development agreements with Catalent to scale-up its spray-dried nasal vaccine, powder formulation for Phase III.
Regulatory press release20.06.2022 klo 16.45Delegation from Bangladesh visits ISR for study preparation